Mazdutide

Mazdutide (IBI362; LY3305677) activates the GLP-1 and glucagon receptors. Its clinical record includes published randomized trials in adults with obesity, overweight, or type 2 diabetes. The findings below refer to studied products, populations, endpoints, and follow-up periods; they do not establish outcomes for products sold outside regulated channels.

Weight-management evidence

The Chinese GLORY-1 phase 3 trial reported greater weight reduction with mazdutide than placebo at 48 weeks. In the separate GLORY-2 phase 3 trial, Chinese adults with obesity, including a minority with type 2 diabetes, had a mean weight change at week 60 of -16.65% with mazdutide and -1.50% with placebo. GLORY-2 reported vomiting, nausea, and diarrhea more often with mazdutide, and adverse-event discontinuation was 2.9% versus 0%. GLORY-1, PMID 40421736 · GLORY-2, PMID 42251595

A Chinese phase 2 trial in 80 adults with obesity without diabetes reported a 24-week weight change of -12.78% versus +1.80% with placebo. A distinct US phase 2 trial randomized 179 adults with obesity or overweight without type 2 diabetes. Its primary 32-week efficacy-estimand analysis reported mean changes of -7.3%, -15.6%, and -18.1% across study groups versus -0.9% with placebo; adverse-event discontinuation was highest in the top-dose group at 20%. The shorter analysis, different estimand, and smaller US sample prevent a direct ranking against the Chinese studies. Chinese phase 2, PMID 41875890 · US phase 2, PMID 42628555

Type 2 diabetes evidence

An earlier Chinese phase 2 randomized trial studied adults with type 2 diabetes inadequately controlled with diet and exercise or stable metformin. In a separate phase 3 placebo-controlled trial of 320 Chinese adults, mean HbA1c changes at week 24 were -1.57% and -2.15% in the two mazdutide groups versus -0.14% with placebo. Another phase 3 trial randomized 731 Chinese adults with type 2 diabetes receiving background oral medicines; mazdutide improved the 28-week HbA1c and weight endpoints versus dulaglutide in that study. Phase 2, PMID 37943529 · Placebo trial, PMID 41407859 · Dulaglutide trial, PMID 41407860

A June 2026 conference abstract, rather than a full trial report, gives DREAMS-3 results from 349 Chinese adults with early type 2 diabetes and obesity. It reports that mazdutide was superior to semaglutide 1 mg on the proportion reaching both HbA1c below 7% and at least 10% weight loss at week 32; the abstract also reports more nausea and vomiting with mazdutide. The open-label design, selected population, semaglutide dose, and abstract-only reporting limit broader comparative claims. This is a distinct trial, not a second publication of DREAMS-1 or DREAMS-2. ADA 2026 abstract, DOI 10.2337/db26-1226-OR

Limits and safety

Gastrointestinal adverse events recur across the trial program. A 2026 systematic review pooled nine randomized trials and 2,292 participants, but the authors graded several obesity comparisons as very-low certainty because of heterogeneity and few trials. Its participants overlap with primary trial reports; they are not an additional independent trial population. A mouse and hepatocyte study of liver disease cannot establish a human liver indication. Review, PMID 42410325 · Mouse and cell study, PMID 41901218

Regulatory scope

An Innovent filing reports Chinese NMPA approval for chronic weight management in adults meeting the filing’s BMI/comorbidity criteria and for glycemic control in adults with type 2 diabetes. This is sponsor-reported regulatory status; the review did not retrieve an independent NMPA label. The FDA’s March 2026 warning letter calls mazdutide products offered by a cited US seller unapproved new drugs. Neither the Chinese report nor a trial registration implies FDA or EMA approval. Innovent filing · FDA warning letter

Registry records for other metabolic and organ outcomes describe research questions, not posted efficacy results. This dossier does not provide dosing, purchasing, or self-treatment guidance and is not medical advice.